Occurrence of Plasmid-Mediated AmpC β-Lactamases Among Escherichia coli and Klebsiella pneumoniae Clinical Isolates in a Tertiary Care Hospital in Bangalore

Indian Journal of Microbiology

Volumn 52, Issue 2, 2012, Pages 174-179

  Sasirekha, B ^a   Shivakumar, Srividya ^a  

^a JAIN UNIVERSITY   (India)

Author keywords

AmpC; Antibiotic resistance; Cefoxitin; E. coli; K. pneumoniae; Plasmid curing

Indexed keywords

ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; NEGIBACTERIA;

EID: 84863221950     PISSN: 00468991     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12088-011-0214-2     Document Type: Article

References (38)

1. Girlich D, Naas T, Bellais S, Poirel L, Karim A, Nordmann P (2000) Heterogeneity of AmpC cephalosporinases of Hafnia alvei clinical isolates expressing inducible or constitutive ceftazidime resistance phenotypes. Antimicrob Agents Chemother 44: 3220-3223.
2. Perez-Perez FJ, Hanson ND (2002) Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 40: 2153-2162.
3. Thomson KS, Smith Moland E (2000) Version 2000: the new beta lactamases of Gram-negative bacteria at the dawn of the new millennium. Microbes Infect 2: 1225-1235.
4. Bush K (2001) New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 32: 1085-1089.
5. Bauernfeind A, Chong Y, Lee K (1998) Plasmid-encoded AmpC beta-lactamases: how far have we gone 10 years after the discovery? Bonsai Med J 39: 520-525.
6. Gazouli M, Tzouvelekis LS, Prinarakis E, Miriagou V, Tzelepi E (1996) Transferable cefoxitin resistance in Enterobacteria from Greek hospitals and characterization of a plasmid-mediated group 1 beta-lactamase (LAT-2). Antimicrob Agents Chemother 40: 1736-1740.
7. Alvarez M, Tran JH, Chow N, Jacoby GA (2004) Epidemiology of conjugative plasmid-mediated AmpC beta-lactamases in the United States. Antimicrob Agents Chemother 48(2): 533-537.
8. Philippon A, Arlet G, Jacoby GA (2002) Plasmid-determined AmpC-type beta-lactamases. Antimicrob Agents Chemother 46(1): 1-11.
9. Bush K, Jacoby GA, Medeiros AA (1995) A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 39: 1211-1233.
10. Coundron PE, Hanson ND, Climo MW (2003) Occurrence of extended-spectrum and AmpC β-lactamases in blood stream isolates of Klebsiella pneumoniae: isolates harbor plasmid-mediated FOX-5 and ACT-1 AmpC β-lactamsases. J Clin Microbiol 41: 772-777.
11. Moland ES, Black JA, Ourada J, Reisbig MD, Hanson ND, Thomson KS (2002) Occurrence of newer β-lactamases in Klebsiella pneumoniae isolated from 24 US hospitals. Antimicrob Agents Chemother 46: 3837-3842.
12. Thomson KS (2001) Controversies about extended-spectrum and AmpC beta-lactamases. Emerg Infect Dis 7: 333-336.
13. Collee JG, Miles RS, Watt B (1996) Tests for identification of bacteria. In: Collee JG, Marmion BP, Fraser AG, Simmons A (eds) Mackie and McCartney practical medical microbiology. Longman Singapore Publishers, Singapore, pp 131-150.
14. Clinical and Laboratory Standards (2006) Performance standards for antimicrobial susceptibility testing: sixteenth informational supplement. Clinical and laboratory Standards Institute, Wayne, M110-S16.
15. Clinical and Laboratory Standards (2005) Performance standards for antimicrobial susceptibility testing. Fifteenth informational supplement. Clinical and Laboratory Standards Institute, Wayne, M100-S15.
16. Shahid M, Malik A, Agrawal M, Singhal S (2004) Phenotypic detection of the extended-spectrum and AmpC β-lactamases by a new spot inoculation method and modified three-dimensional extract test: comparison with conventional three-dimensional extract test. J Antimicrob Chemother 54: 684-687.
17. Davis LG, Dibner MD, Battey JF (1986) Large scale alkaline lysis method of plasmid purification. In: Davis LG, Dibner MD, Battery JF (eds) Basic methods in molecular biology, Sect. 8-3. Elsevier, New York, p 99.
18. Shahid M, Malik A, Sheeba (2003) Multidrug-resistant Pseudomonas aeruginosa strains harboring R plasmids and AmpC β-lactamases isolated from hospitalized burn patients in a tertiary care hospital of North India. FEMS Microbiol Lett 228: 181-186.
19. Jacoby GA (2009) AmpC β-lactamases. Clin Microbiol Rev 22: 161-182.
20. Singhal S, Mathur T, Khan S, Upadhyay DJ, Chugh S, Gaind R, Rattan A (2005) Evaluation of methods for AmpC β-lactamase in gram-negative clinical isolates from tertiary care hospitals. Indian J Med Microbiol 23: 120-124.
21. Gupta V (2007) An update on newer β-lactamases. Indian J Med Res 126: 417-427.
22. Manchanda V, Singh NP (2003) Occurrence and detection of AmpC β lactamases among gram negative clinical isolates using a modified three dimensional test at Guru Tegh Bahadur Hospital, Delhi, India. J Antimicrob Chemother 51: 415-418.
23. Subha A, Devi VR, Ananthan (2003) AmpC β lactamase producing multidrug resistant strains of Klebsiella spp and E. coli isolated from children under five in Chennai. Indian J Med Res 117: 13-18.
24. Ananthan S, Subha A (2005) Cefoxitin resistance mediated by loss of a porin in clinical strains of Klebsiella pneumoniae and E. coli. Indian J Med Microbiol 23(1): 20-23.
25. Ratna AK, Menon I, Kapur I, Kulkarni R (2003) Occurrence and detection of AmpC β lactamases at a referral hospital in Karnataka. Indian J Med Res 118: 29-32.
26. Hernandez A, Benedl VJ, Martinez LM, Pascual A, Aguilar A, Tomas M, Alberti S (1999) Development of resistance during antimicrobial therapy caused by insertion sequence interruption of porin genes. Antimicrob Agents Chemother 43: 937-939.
27. Kang CI, Pai H, Kim SH, Kim HB, Kim EC, Oh MD, Choe KW (2004) Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase. J Antimicrob Chemother 54: 1130-1133.
28. Queenan AM, Foleno B, Gownley C, Wira E, Bush K (2004) Effects of inoculum and beta-lactamase activity in AmpC and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. J Clin Microbiol 42: 269-275.
29. Song W, Moland ES, Hanson ND, Lewis JS, Jorgensen JH, Thomson KS (2005) Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia. J Clin Microbiol 43: 4891-4894.
30. Goossens H, Grabein B (2005) Prevalence and antimicrobial susceptibility data for extended spectrum beta lactamase and AmpC producing Enterobacteriaceae from the MYSTIC program in Europe and the US (1997-2004). Diagn Microbiol Infect Dis 53(4): 257-264.
31. Thomson KS, Sanders CC (1992) Detection of extended spectrum β-lactamases in members of family Enterobacteriaceae: comparison of the double disk and three dimensional tests. Antimicrob Agents Chemother 36: 1877-1882.
32. Pena C, Pujol M, Ardanuy C (1998) Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended spectrum β-lactamases. Antimicrob Agents Chemother 42: 53-58.
33. Winokur PL, Canton R, Casellas JM, Legakis N (2001) Variations in the prevalence of strains expressing an extended spectrum β-lactamase phenotype and characterisation of isolates from Europe, the Americans and the Western Pacific region. Clin Infect Dis 32: 594-603.
34. Abigail S, Mathai E, Jesudason MV, John TJ (1995) Ceftazidime resistance among Klebsiella pneumoniae in South India. Indian J Med Res 102: 53-55.
35. Subha A, Ananthan S (2002) Extended spectrum β-lactamase mediated resistance to third generation cephalosporins among Klebsiella pneumoniae in Chennai. Indian J Med Microbiol 20: 92-95.
36. Tan TY, Ng SY, Teo L, Koh Y, Teok CH (2008) Detection of plasmid-mediated AmpC in Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis. J Clin Pathol 61: 642-644.
37. Peterson LR (2005) Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance. Clin Microbiol Infect 11(Suppl 5): 4-16.
38. Paterson DL (2004) "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 38(Suppl 4): S341-S345.